Statins Prolong Life after Heart Attack

Statins cannot prevent all heart attacks, but patients who have been taking them live longer than others after such an event, according to research presented Nov. 12 during the Resuscitation Science Symposium at the American Heart Association’s Scientific Sessions 2016 in New Orleans, LA.

A study analyzing the records of nearly 138,000 patients who suffered out-of-hospital-cardiac arrest in the Taiwan National Health Insurance Research Database found that the prior use of statins was associated with higher rates of survival after cardiac arrest than was non-use. Statin users were significantly more likely than non-users to be still alive a year after the episode. Within the statin group, a subgroup of patients with type 2 diabetes showed the most improvement in survival rate.

The study also found that with the prior use of statins, patients were:

• About 19% more likely to survive to reach a hospital;
• About 47% more likely to survive long enough to be discharged from hospital;
• 50% more likely to survive for at least a year afterwards; and
• Most likely to see a benefit from prior use of statins if they had type 2 diabetes.

“There is some risk associated with statins, but this study confirms the benefit,” said Ping-Hsun Yu, MD, study senior author and a researcher at the Taipei Hospital Ministry of Health and Welfare in Taiwan as quoted in a news release.

Yu and his colleagues sorted the records according to whether or not the patients had used statins within 90 days of a cardiac event and researchers accounted for gender, age, underlying conditions, years of hospitalization, post-resuscitation factors, and several other variables.

More than 95% of the research population in the analysis were Asian, so researchers say these results might not apply to other ethnic groups or to multi-ethnic populations like that of the United States. The pre-existing database also did not distinguish among different dosages or types of statin. A prospect for further study, said Yu, “may be to divide the statins into different subgroups to see if different potencies or types result in different outcomes.”